Human Induced Pluripotent Stem Cell-Derived Exosomes as a New Therapeutic Strategy for Various Diseases

Wang, Aline Yen Ling

doi:10.3390/ijms22041769

Cited by 24 publications

(17 citation statements)

References 100 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As a new regenerative medicine and drug delivery system, exosomes have received much attention in recent years. hiPSC-exosomes from pluripotent stem cells may inherit their advantages, which may enable more treatment Frontiers in Bioengineering and Biotechnology frontiersin.org approaches for diseases (Jung et al, 2017;Wang, 2021;Zhou et al, 2021). Exosomes derived from hiPSCs have the potential to treat skin and eye diseases, and especially cardiovascular diseases (Germena and Hinkel, 2021).…”

Section: Discussionmentioning

confidence: 99%

Safety and biodistribution of exosomes derived from human induced pluripotent stem cells

Yin

Song

et al. 2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

As a new cell-free therapy, exosomes have provided new ideas for the treatment of various diseases. Human induced pluripotent stem cells (hiPSCs) cannot be used in clinical trials because of tumorigenicity, but the exosomes derived from hiPSCs may combine the advantages of iPSC pluripotency and the nanoscale size of exosomes while avoiding tumorigenicity. Currently, the safety and biodistribution of hiPSC-exosomes in vivo are unclear. Here, we investigated the effects of hiPSC-exosomes on hemolysis, DNA damage, and cytotoxicity through cell experiments. We also explored the safety of vein injection of hiPSC-exosomes in rabbits and rats. Differences in organ distribution after nasal administration were compared in normal and Parkinson’s disease model mice. This study may provide support for clinical therapy and research of intravenous and nasal administration of hiPSC-exosomes.

show abstract

Section: Discussionmentioning

confidence: 99%

Safety and biodistribution of exosomes derived from human induced pluripotent stem cells

Yin

Song

et al. 2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

show abstract

“…While research on NKEVs has increased, investigations into iPSC-NK cell-derived EVs (iPSC-NKEVs) remain unreported, raising the question of whether iPSC-NK cells also produce EVs (Figure 2). This may represent an important, currently underexplored therapeutic opportunity considering recent research from both NKEVs and EVs from other iPSC-derived cells (130,131).…”

Section: Ipscs In Nkev Developmentmentioning

confidence: 99%

iPSCs in NK Cell Manufacturing and NKEV Development

Boyd-Gibbins¹,

Karagiannis

Hwang³

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

Natural killer (NK) cell immunotherapies for cancer can complement existing T cell therapies while benefiting from advancements already made in the immunotherapy field. For NK cell manufacturing, induced pluripotent stem cells (iPSCs) offer advantages including eliminating donor variation and providing an ideal platform for genome engineering. At the same time, extracellular vesicles (EVs) have become a major research interest, and purified NK cell extracellular vesicles (NKEVs) have been shown to reproduce the key functions of their parent NK cells. NKEVs have the potential to be developed into a standalone therapeutic with reduced complexity and immunogenicity compared to cell therapies. This review explores the role iPSC technology can play in both NK cell manufacturing and NKEV development.

show abstract

“…The use of induced pluripotent stem cells (iPSCs) is a promising alternative to model and study NDDs in vitro [17,18]. iPSCs can be obtained from the reprogramming of somatic cells, such as fibroblasts and peripheral blood, from healthy and patient donors [15,19]. Furthermore, as iPSCs have self-renewal properties and can differentiate into any cell type, iPSCs can differentiate into motor neurons, oligodendrocytes, astrocytes and microglia.…”

Section: Introductionmentioning

confidence: 99%

An insight into the iPSCs-derived two-dimensional culture and three-dimensional organoid models for neurodegenerative disorders

et al. 2022

View full text Add to dashboard Cite

The use of induced pluripotent stem cells (iPSCs) is a promising approach when used as models to study neurodegenerative disorders (NDDs) in vitro . iPSCs have been used in in vitro two-dimensional cultures; however, these two-dimensional cultures do not mimic the physiological three-dimensional cellular environment. The use of iPSCs-derived three-dimensional organoids has risen as a powerful alternative to using animal models to study NDDs. These iPSCs-derived three-dimensional organoids can resemble the complexity of the tissue of interest, making it an approachable, cost-effective technique, to study NDDs in an ethical manner. Furthermore, the use of iPSCs-derived organoids will be an important tool to develop new therapeutics and pharmaceutics to treat NDDs. Herein, we will highlight how iPSCs-derived two-dimensional cultures and three-dimensional organoids have been used to study NDDs, as well as the advantages and disadvantages of both techniques.

show abstract

Human Induced Pluripotent Stem Cell-Derived Exosomes as a New Therapeutic Strategy for Various Diseases

Cited by 24 publications

References 100 publications

Safety and biodistribution of exosomes derived from human induced pluripotent stem cells

Safety and biodistribution of exosomes derived from human induced pluripotent stem cells

iPSCs in NK Cell Manufacturing and NKEV Development

An insight into the iPSCs-derived two-dimensional culture and three-dimensional organoid models for neurodegenerative disorders

Contact Info

Product

Resources

About